Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies

February 27, 2024

Advancing RNA Therapy Research with LipidLaunch™ Tools

ANN ARBOR, MI, FEBRUARY 22, 2024 – Cayman Chemical, a leading supplier of research tools for lipid nanoparticles (LNPs), announced today the introduction of LipidLaunch™ research-ready LNPs and reagent kits. The LipidLaunch™ product line is the latest addition to the company’s portfolio of LNP research tools and reflects the company’s legacy of providing high-quality lipids for academic, pharma, and biotech researchers worldwide.


The LipidLaunch™ product line helps researchers pursue LNPs for the delivery of nucleic acid therapies in untold health applications, ranging from vaccine development to cancer and cell or gene therapies. Cayman’s LipidLaunch™ products support LNP research and development from discovery to bioanalysis with a range of purpose-built solutions. The full LipidLaunch™ product line includes:

  • Preloaded LNPs: Prepared as preformulated LNPs encapsulating reporter gene mRNA, preloaded LNPs are intended for pilot or proof-of-concept experiments to help identify target cells and optimize LNP culture conditions.
  • Loadable LNPs: Comprising empty, preformulated LNPs, these cargo-ready, loadable LNPs enable researchers to encapsulate and transfect cells with their RNA cargo of choice.
  • LNP Exploration Kits: Containing a complete set of individually packaged reagents, LNP Exploration Kits are designed for preparing tailor-made LNPs with custom cargo without specialized equipment.
  • LNP Uptake Kits: Expanding on the LNP Exploration Kit format, the LNP Uptake Kits feature a fluorescently labeled lipid that is incorporated during LNP preparation to visualize LNP cellular uptake.


With accessibility top of mind, the LipidLaunch™ product line reduces LNP barriers to entry by offering simple and cost-effective solutions for researchers at any stage of their studies. LipidLaunch™ research-ready LNPs and reagent kits employ the same lipid formulations as LNPs of broad and current interest, including those used for the mRNA-based COVID-19 vaccines, and are available in multiple formats to give researchers choice in cargo selection and LNP formulation.


LipidLaunch™ research tools were designed to require minimal hands-on time and expertise. Preloaded and Loadable LNPs are preformulated LNPs that require no LNP mixing steps, maximizing ease-of-use, and LNP Exploration and Uptake Kits enable the preparation of LNPs with hand mixing techniques or, if available, microfluidic mixers.


LipidLaunch™ research tools are available now through Cayman or worldwide through their distribution network. Cayman also offers an extensive catalog of lipids for LNP formulation, including ionizable cationic lipids, helper lipids, sterols, and PEGylated lipids, as well as LNP Development Services.


LipidLaunch™ is a trademark of Cayman Chemical Company, Inc.


About Cayman

Cayman Chemical helps make research possible by supplying scientists worldwide with biochemical tools used to understand cancer, neurochemistry, oxidative injury, endocrinology, atherosclerosis, and other human health challenges. Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others for use as research reagents and qualified standards. In addition, we offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques. Cayman performs API development and production in both Ann Arbor, Michigan and Neratovice, Czech Republic. Learn more at www.caymanchem.com.

RECENT ARTICLES

MichBio Hiring: Intern, Association Membership & Resource Analytics

April 15, 2025
MichBio seeks a highly motivated individual who can work creatively in a small team environment and assist in data mining, compilation, and research.

Bio Survey Underscores Impacts of Tariffs for Businesses

April 11, 2025
The Biotechnology Innovation Organization (BIO), of which MichBio is a state affiliate recently released the results of a survey of its members, noting that “U.S. Biotechs Sound the Alarm” on tariff impacts. The findings include: Tariffs on European Union and Canadian imports would increase manufacturing costs for 94% and 82% of biotech firms, respectively. 70% of companies anticipate higher manufacturing costs due to tariffs on China. Tariffs on the European Union would force 50% of biotech firms to identify new research and manufacturing partners. More than 50% of biotech firms predict “increased difficulty” in funding and conducting research if EU tariffs are enacted. 80% of biotech firms would need at least 12 months to find alternative suppliers; 44% would need over two years. The survey noted that sudden tariffs would fundamentally punish American companies, threaten vital research projects and imperil United States leadership in biomedical science. Read BIO’s press release , along with an one-pager summarizing the survey results. 

Amid Proposed Cuts, Commission Calls For $15B NIH Support

April 10, 2025
A federal commission, in a new report , is calling for $15 billion in new financing to reinforce the United States’ biotech leadership amid encroaching competition from China. This comes against a backdrop where the Trump Administration has proposed severe cuts to NIH operations and funding. The National Security Commission on Emerging Biotechnology was created by Congress in 2022 to explore how biotechnology advancements could shape the economy and national security. The body quickly focused on China, as that government has gone about gathering Americans’ genetic information and intellectual property in the biotech space and resourcing their cluster’s rapid growth. The report’s 49 recommendations, organized across six strategic pillars, offer a bold and actionable framework to protect U.S. biotech intellectual property and bolster drug development, agriculture, and biological weapons defense: Prioritize biotechnology at the national level Mobilize the private sector to get U.S. products to scale Maximize the benefits of biotechnology for defense Out-innovate our strategic competitors Build the biotechnology workforce of the future Mobilize the collective strengths of our allies and partners The report calls for $1 billion to create an investment fund, more than $6 billion for large-scale research challenges, and a build-up of biomanufacturing sites across the country. Also, it calls for new legislation barring companies that work with U.S. national security agencies or health agencies from using certain Chinese biotech suppliers. The commission doesn’t have the power to authorize any changes but can make recommendations and advise members of Congress. BIO issued a statement in support.